A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

Inclusion Criteria: * Ability to comprehend the study procedures, provide a signed ICF, and comply with all Protocol requirements. * Healthy, age 18 to 55 years, inclusive, at the time of signing the ICF, with no significant past or current medical history. * Body mass index between 18.0 and 30.0 kg/m2, inclusive, at screening. Note: Up to 25% of the participants in each cohort may be enrolled with a BMI \> 30 to ≤ 32.0 kg/m2. * No clinically significant findings during screening and check-in (Day -1) for evaluations (eg, clinical, laboratory, vital signs, ECG). Tests with results that fail eligibility requirements may be repeated once during screening. * Ability to receive study drug via IV or SC administration as per Protocol requirements. * Willingness to avoid pregnancy or fathering children. * Ability to understand and willingness to comply with study procedures and restrictions (including confinement to clinical site and restrictions of physical activity, use of recreational drugs, alcohol, and medications). Exclusion Criteria: * History of rheumatologic/autoimmune disorders, except for minor eczema and rosacea. * Participants with laboratory values outside the normal reference range at screening or check-in (see Appendix B for required analytes), including hemoglobin, WBC count, platelet count, or absolute neutrophil count, will be evaluated for clinical significance and eligibility by the investigator or qualified designee. * History of malignancy within 5 years of…